Document Detail


Hyperuricemia in kidney transplantation.
MedLine Citation:
PMID:  15604612     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Hyperuricemia is a common problem among renal transplant recipients. Its prevalence is clearly attributable to cyclosporine (CsA) use, although individual patients may have other risk factors as well. CsA lowers the urinary clearance of uric acid. The specific mechanism for this is unknown, but may involve alteration in tubular transport. Hyperuricemia may add on to several other factors in contributing to progressive deterioration of graft function and ultimately graft loss. The therapy of hyperuricemia may be particularly challenging in transplant patients.
Authors:
Norberto Perico; Igor Codreanu; Mariarosa Caruso; Giuseppe Remuzzi
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Contributions to nephrology     Volume:  147     ISSN:  0302-5144     ISO Abbreviation:  Contrib Nephrol     Publication Date:  2005  
Date Detail:
Created Date:  2004-12-17     Completed Date:  2005-01-26     Revised Date:  2005-11-16    
Medline Journal Info:
Nlm Unique ID:  7513582     Medline TA:  Contrib Nephrol     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  124-31     Citation Subset:  IM    
Affiliation:
Department of Medicine and Transplantation, Ospedali Riuniti di Bergamo, Mario Negri Institute for Pharmacological Research, Bergamo, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Chronic Disease
Cyclosporine / adverse effects
Graft Rejection
Humans
Hyperuricemia / etiology*
Kidney Transplantation / adverse effects*
Chemical
Reg. No./Substance:
59865-13-3/Cyclosporine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Rasburicase therapy in acute hyperuricemia and renal dysfunction.
Next Document:  Uric acid elimination in the urine. Pathophysiological implications.